Biotechnology company developing next-generation neuropsychiatric therapeutics, co-founded and led by Yale psychiatry chair Dr. John Krystal and Dina Burkitbayeva. Its lead asset FREE001 combines ketamine with temsirolimus (an mTOR inhibitor) to extend the antidepressant duration of ketamine; the FDA cleared its IND in April 2024 and a Phase 2a treatment-resistant depression trial is underway. The company emerged from stealth in 2022 with $10.5 million in seed financing.
Freedom Biosciences News 6 articles
- Bipartisan 'Freedom to Heal Act' would open Right to Try access to psilocybin and MDMA
- Freedom Biosciences Announces FDA Approval of IND Application for FREE001 in Patients with Treatment-Resistant Depression
- Freedom Biosciences Appoints Dr. David Hough as Chief Medical Officer
- Field Trip Announces the Launch of Freedom by Field Trip™, a First-of-Its-Kind Ketamine Therapy Program
- Freedom Biosciences Emerges from Stealth with $10.5 Million Seed Financing to Develop Next-Generation Ketamine and Psychedelic-based Mental Health Treatments
- FTO Files Requests for Reconsideration of U.S. Patent Trial and Appeal Board’s Decisions Concerning Petitions for Post Grant Review of Compass Patents